<DOC>
	<DOCNO>NCT00395629</DOCNO>
	<brief_summary>Brief Summary : This study design explore safe dose characterize preliminary safety efficacy ICL670 adult patient previously document history homozygous C282Y .</brief_summary>
	<brief_title>Safety Efficacy Deferasirox ( ICL670 ) Patients With Iron Overload Resulting From Hereditary Hemochromatosis</brief_title>
	<detailed_description />
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Hemochromatosis</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Age 18 year age old Male female patient homozygous C282Y mutation . Iron overload document serum ferritin transferrin saturation No known allergy contraindication administration deferasirox Ability comply studyrelated procedure , medication , evaluation Effective use birth control measure . Iron overload due hereditary hemochromatosis Males hemoglobin &lt; 13 mg/dL , females hemoglobin &lt; 12 mg/dL Desferal treatment within 1 month screen visit Patients currently previously treat deferiprone deferasirox Significant medical condition interfere ability partake study Presence surgical medical condition might significantly alter absorption , distribution , metabolism excretion study drug Clinical evidence Active Hepatitis B C Positive HIV serology Pregnant breast feeding patient Patients treated systemic investigational drug within 4 week prior topical investigational drug within 7 day prior screen visit Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Deferasirox</keyword>
	<keyword>ICL670A</keyword>
	<keyword>Iron chelators</keyword>
	<keyword>Deferiprone</keyword>
	<keyword>Transfusional Hemochromatosis</keyword>
</DOC>